Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients
Year: 2026
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Meningiomas are hormonally sensitive tumors that occur disproportionately among women with breast cancer. We compared the risk of incident meningioma among patients initiating aromatase inhibitors (AIs) versus tamoxifen. METHODS: Using the TriNetX Global Collaborative Network (181 healthcare organizations), we identified adults with breast cancer recorded during 2010-2015 who initiated anastrozole, letrozole, or exemestane versus tamoxifen, without exposure to the alternate endocrine therapy class. Cohorts were matched 1:1 on 27 covariates. Incident meningioma was assessed at 1, 2, and 3 years using risk estimates and Cox proportional hazards models. RESULTS: After matching, 23,204 patients were included per cohort; 23,110 AI users and 23,114 tamoxifen users without prior meningioma were included in the outcome analyses. Meningioma risk was higher with AIs at 1 year (1.51 vs 0.82 per 1,000; HR 1.846, 95% CI 1.056-3.227), 2 years (2.64 vs 1.56; HR 1.705, 95% CI 1.129-2.574), and 3 years (3.29 vs 2.29; HR 1.449, 95% CI 1.021-2.058). Absolute risk differences were 0.69, 1.08, and 1.00 per 1,000, respectively. CONCLUSION: AI initiation was associated with a modestly higher but progressively attenuating relative risk of meningioma than tamoxifen, with a small absolute excess. These findings should not alter endocrine therapy selection but may inform evaluation of new dural-based lesions in AI users.
Source: Cancer Causes & Control
Authors: Jeremiah Hilkiah Wijaya(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing), Soni Roy Kurniawan Hulu(Investigation, Methodology, Validation, Writing – review & editing), Brandon Lucke-Wold(Methodology, Supervision, Validation, Writing – review & editing), Made Agus Mahendra Inggas(Investigation, Validation, Writing – review & editing), Vivien Puspitasari(Investigation, Validation, Writing – review & editing)
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,890
OpenAlex ID: W7236448977
